



PATENT
Docket No. 110.00440102

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Lawrence P. Wackett, et al.)	Group Art Unit:	1652
)		
Serial No.:	09/866,307)	Examiner:	Unknown
)		
Filed:	May 25, 2001)		
)		
For:	DNA MOLECULES AND PROTEIN DISPLAYING IMPROVED TRIAZINE COMPOUND DEGRADING ABILITY			

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE REQUIREMENTS

BOX SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, and in accordance with 37 C.F.R. §1.821, a Sequence Listing in computer readable form and a copy of the Sequence Listing in written form are submitted herewith.

The enclosed Sequence Listing is identical to the Sequence Listing submitted in the parent of this divisional application, U.S. Patent Application No. 09/155,036, and in priority application, PCT Application No. PCT/US98/00944, except that (1) the name of the applicant and current application data have been changed to correctly identify the present application, (2) prior application data has been added to fully reference the parent and prior applications, and (3) attorney/agent information and telecommunication information have been changed to update the identify of Applicants' attorney/agent for the present application.

Response to Notice to Comply with Sequence Requirements

Page 2

Applicants: Lawrence P. Wackett, et al.

Serial No.: 09/866,307

Title: DNA MOLECULES AND PROTEIN DISPLAYING IMPROVED TRIAZINE COMPOUND DEGRADING ABILITY

In accordance with 37 C.F.R. §1.821(f), the information recorded in computer readable form is identical to the written Sequence Listing submitted herewith and, and with the exception of the changes described above, is also identical to the written Sequence Listing that was filed with the application on May 25, 2001. It is further submitted that the Sequence Listing does not include new matter.

CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to Assistant Commissioner for Patents, BOX SEQUENCE, Washington, D.C. 20231, on this 17 day of September, 2001.

David L. Provence
David L. Provence

Date

DLP/mi

September 17, 2001

Respectfully submitted,
LAWRENCE P. WACKETT, ET AL.
By Applicants' Representatives,
Mueting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Phone: (612) 305-1220
Facsimile: (612) 305-1228
Customer Number 26813

By:

David L. Provence

David L. Provence

Reg. No. 43,022

Direct Dial (612) 305-1005

AA

Seefor
Box seq

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Lawrence P. Wackett, et al. Group Art Unit: 1652

Serial No.: 09/866,307 Examiner: Unknown

Confirmation No.: 4705 Docket No.: 110.00440102

Filed: 25 May 2001

Title: DNA MOLECULES AND PROTEIN DISPLAYING IMPROVED TRIAZINE COMPOUND
DEGRADING ABILITY

BOX SEQUENCE

Assistant Commissioner for Patents
Washington, D.C. 20231

We are transmitting the following documents along with this Transmittal Sheet (which is submitted in triplicate):

- ☒ An itemized return postcard.
- ☐ A Petition for Extension of Time for __ month(s) and a check in the amount of \$__ for the required fee.
- ☐ An Information Disclosure Statement (__ pgs); copies of __ applications; 1449 forms (__ pgs); and copies of __ documents cited on the 1449 forms.
- ☐ A check in the amount of \$__, for __.
- ☒ Other: Response to Notice to Comply with Sequence Requirements (2 pgs); Copy of Notice to Comply with Requirements (2 pgs); Computer readable form of Sequence Listing (1 diskette); and copy of Sequence Listing in written form (32 pgs).
- ☐ Amendment ☐ No Additional fee is required. ☐ The fee has been calculated as shown:

Fee Calculation for Claims Pending After Amendment					
	Pending Claims after Amendment (1)	Claims Paid for Earlier (2)	Number of Additional Claims (1-2)	Cost per Additional Claim	Additional Fees Required
Total Claims				x \$18 =	
Independent Claims				x \$80 =	
One or More New Multiple Dependent Claims Presented? If Yes, Add \$270 Here →					
Total Additional Claim Fees Required					

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers and please charge any additional fees or credit overpayment to Deposit Account No. 13-4895. Triplicate copies of this sheet are enclosed.

CERTIFICATE UNDER 37 C.F.R. §1.8: The undersigned hereby certifies that this Transmittal Letter and the paper(s), as described hereinabove, are being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, BOX SEQUENCE, Washington, D.C. 20231, on this 17 day of September, 2001.

MUETING, RAASCH & GEBHARDT, P.A.
Customer Number: 26813

By: David L. Provence
Name: David L. Provence
Reg. No.: 43,022
Direct Dial: 612-305-1005
Facsimile: 612-305-1228

(LARGE ENTITY TRANSMITTAL UNDER RULE 1.8)



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/866,307	05/25/2001	Lawrence P. Wackett	110.00440102

CONFIRMATION NO. 4705

26813

MUETING, RAASCH & GEBHARDT, P.A.
P.O. BOX 581415
MINNEAPOLIS, MN 55401

FORMALITIES LETTER



OC00000006301069

Date Mailed: 07/16/2001

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). Applicant must provide such statement. If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE